Generation Bio Co. financial data

Symbol
GBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Binney Street, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 778 % -47.2%
Debt-to-equity 91.6 % +110%
Return On Equity -92.9 % -106%
Return On Assets -48.5 % -54.3%
Operating Margin -1.3K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.7M shares +1.23%
Common Stock, Shares, Outstanding 66.7M shares +1.4%
Entity Public Float 299M USD -2.16%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 66.5M shares +1.33%
Weighted Average Number of Shares Outstanding, Diluted 66.5M shares +1.33%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 13.2M USD +365%
Research and Development Expense 80.5M USD -7.07%
General and Administrative Expense 45M USD -10.8%
Operating Income (Loss) -171M USD -25.4%
Nonoperating Income (Expense) 12.3M USD +32.6%
Net Income (Loss) Attributable to Parent -158M USD -24.9%
Earnings Per Share, Basic -2.39 USD/shares -14.9%
Earnings Per Share, Diluted -2.39 USD/shares -14.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.5M USD -80.3%
Marketable Securities, Current 188M USD +11.4%
Accounts Receivable, after Allowance for Credit Loss, Current 1.34M USD
Other Assets, Current 290K USD +12%
Assets, Current 223M USD -30.4%
Property, Plant and Equipment, Net 17.1M USD -22.2%
Operating Lease, Right-of-Use Asset 22.1M USD -60.4%
Other Assets, Noncurrent 200K USD -39.9%
Assets 265M USD -34.5%
Accounts Payable, Current 1.91M USD -18%
Employee-related Liabilities, Current 3.88M USD -10.7%
Contract with Customer, Liability, Current 5.68M USD
Liabilities, Current 30.1M USD +13.7%
Contract with Customer, Liability, Noncurrent 55.1M USD
Operating Lease, Liability, Noncurrent 85.3M USD +17.7%
Liabilities 150M USD -0.49%
Accumulated Other Comprehensive Income (Loss), Net of Tax -280K USD -1117%
Retained Earnings (Accumulated Deficit) -666M USD -31.2%
Stockholders' Equity Attributable to Parent 115M USD -54.6%
Liabilities and Equity 265M USD -34.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7M USD -14.5%
Net Cash Provided by (Used in) Financing Activities -125K USD -100%
Net Cash Provided by (Used in) Investing Activities -553K USD +90.2%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 66.7M shares +1.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.7M USD -79.7%
Deferred Tax Assets, Valuation Allowance 176M USD +27.3%
Operating Lease, Liability 60.8M USD
Payments to Acquire Property, Plant, and Equipment 1.92M USD +154%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -159M USD -25.4%
Lessee, Operating Lease, Liability, to be Paid 137M USD +31.1%
Property, Plant and Equipment, Gross 38.2M USD -2.38%
Operating Lease, Liability, Current 8.63M USD +6.12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.6M USD +2.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.2M USD +13.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 38.9M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16.1M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 96.9M USD +8.26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 16.6M USD +2.83%
Operating Lease, Payments 1.9M USD -38.7%
Additional Paid in Capital 782M USD +2.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5.25M USD -2.2%
Deferred Tax Assets, Net of Valuation Allowance 198M USD +25.3%
Share-based Payment Arrangement, Expense 19.7M USD -17.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%